Cure8
Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort.
Inflammatory bowel diseases

Cure8 research brief

Work disability in patients with newly diagnosed inflammatory bowel disease: Results from the population-based IBSEN III cohort.

2 min read
Mental health and quality of life Clinical study Adult patients Clinicians Researchers Parents Caregivers Newly Diagnosed Post Surgery Patients

Why This Matters

Patients with newly diagnosed UC and CD had higher risk of receiving work-assessment allowance within the first year; psychosocial factors like self-efficacy and HRQoL were linked to work disability risk, suggesting possible targets to help preserve work ability.

Who Should Pay Attention

Newly diagnosed adult IBD patients (UC and CD), clinicians and occupational health professionals, rehabilitation specialists, and researchers focused on functional outcomes.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

This population-based inception cohort study compared rates of work disability (defined as receiving work assessment allowance or disability pension) in patients with newly diagnosed Crohn’s disease (CD) and ulcerative colitis (UC) to the general population at diagnosis and after 1 year.

At diagnosis, work assessment allowance (AAP) risk was higher in UC overall and in CD patients aged 30–39. At 1 year, AAP risk was higher for both UC and CD; disability pension (DP) rates were similar to the background population.

The study found that higher general self-efficacy and better health-related quality of life were linked to lower odds of receiving work disability benefits, while disease-activity measures were not strongly associated. Older age, comorbidities, and lower educational level were associated with greater odds of work disability among UC patients.

Keep In Mind

Summary is based on the article abstract from Inflammatory Bowel Diseases (population-based cohort). The results are associative and based on registry-defined benefits (AAP, DP); read the full paper for methods, limitations, and local applicability.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationInflammatory bowel diseases
AuthorsCharlotte Lund, Milada Hagen, Vibeke Strande +14 more
InstitutionInstitute of Clinical Medicine, University of Oslo, PO Box 1171 Blindern, 0318 Oslo, Norway.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedNov 4, 2026, 12:00 AM
Content availableJournal abstract

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →